1,205 Shares in Zoetis Inc. (NYSE:ZTS) Bought by Opal Wealth Advisors LLC

Opal Wealth Advisors LLC acquired a new position in shares of Zoetis Inc. (NYSE:ZTS) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,205 shares of the company’s stock, valued at approximately $198,000.

Several other institutional investors and hedge funds have also modified their holdings of ZTS. Vanguard Group Inc. increased its holdings in Zoetis by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company’s stock worth $6,739,905,000 after purchasing an additional 120,158 shares in the last quarter. Geode Capital Management LLC increased its holdings in Zoetis by 1.8% in the 4th quarter. Geode Capital Management LLC now owns 10,617,897 shares of the company’s stock worth $1,726,075,000 after purchasing an additional 190,137 shares in the last quarter. Polen Capital Management LLC increased its holdings in Zoetis by 17.5% in the 4th quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company’s stock worth $1,219,237,000 after purchasing an additional 1,116,541 shares in the last quarter. Wellington Management Group LLP increased its holdings in Zoetis by 78.5% in the 4th quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company’s stock worth $1,133,755,000 after purchasing an additional 3,059,255 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in Zoetis by 13.3% in the 4th quarter. Northern Trust Corp now owns 6,426,394 shares of the company’s stock worth $1,047,052,000 after purchasing an additional 755,893 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 652 shares of the company’s stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the sale, the executive vice president now owns 15,129 shares in the company, valued at $2,571,930. This represents a 4.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.18% of the stock is owned by corporate insiders.

Zoetis Trading Down 2.7%

Shares of ZTS stock opened at $164.27 on Friday. The stock has a market cap of $73.13 billion, a price-to-earnings ratio of 30.03, a PEG ratio of 2.78 and a beta of 0.94. The stock has a 50-day moving average of $158.67 and a 200-day moving average of $163.92. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. During the same quarter in the prior year, the company earned $1.38 EPS. The firm’s revenue for the quarter was up 1.4% compared to the same quarter last year. On average, equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 annualized dividend and a dividend yield of 1.22%. Zoetis’s payout ratio is 35.91%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ZTS. Piper Sandler upped their target price on Zoetis from $205.00 to $210.00 and gave the stock an “overweight” rating in a report on Monday, May 12th. UBS Group lowered their target price on Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, May 7th. Stifel Nicolaus lowered their target price on Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a report on Monday, April 14th. Finally, Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $212.75.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.